

Laurent COEN et al.
Serial No.: 09/816,467

Attorney Docket No. 3495.0174-01

After page 37, and before the claims, beginning on a new page, please insert the attached sequence listing.

IN THE CLAIMS:

Please cancel claim 20 without prejudice or disclaimer.

8. (Amended) The method according to claim 6, wherein the molecule is selected from the group consisting of protein SM, BDNF (Brain-derived neurotrophic factor), NT-3 (Neurotrophin-3), NT-4/5, GDNF (Glial cell-line-derived neurotrophic factor), IGF (Insulin-like growth factor), PNI (protease nexin I), SPI3 (Serine Protease Inhibitor protein), ICE (Interleukin-1 β converting enzyme), Bc1-2, GFP (green fluorescent protein), an endonuclease, antibodies, or drugs specifically directed against a neurodegenerative disease.

15. (Amended) The method according to claim 12, wherein said vector is administered into the muscle.

16. (Amended) The method according to claim 12, wherein the molecule is a nucleotide encoding for a protein or a polypeptide linked chemically to the fragment of tetanus toxin and being transported and expressed directly in neurons.

19. (Amended) An amino acid variant fragment having the same properties as the hybrid fragment of tetanus toxin according to claim 17.

21. (Amended) A composition containing an active molecule in association with a hybrid fragment of tetanus toxin according to claim 17.

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-406-4000

145859

Laurent COEN et al.
Serial No.: 09/816,467

Attorney Docket No. 3495.0174-01

24. (Amended) A vector comprising a promoter capable of expression in muscle cells and optionally an enhancer, a nucleic acid sequence coding for the fragment of tetanus toxin according to claim 17, wherein the nucleic acid sequence is associated with a polynucleotide coding for a protein or a polypeptide.

25. (Amended) A method of treatment of a patient or an animal affected with CNS or spinal cord disease, which comprises delivering a composition according to claim 21 to the patient or animal in an amount effective for treatment of the CNS or spinal cord disease.

29. (Amended) The method according to claim 27, wherein the molecule is a nucleotide encoding for a protein or a polypeptide linked chemically to the fragment of tetanus toxin and being expressed directly in neurons.

30. (Amended) The method according to claim 27, wherein the molecule is a nucleotide encoding for a protein or a polypeptide linked chemically to the fragment of tetanus toxin and being expressed directly in neurons.

31. (Amended) A cell or vector comprising a promoter capable of expression in neuronal cells or precursors of neuronal cells and optionally an enhancer, a nucleic acid sequence coding for the fragment of tetanus toxin according to claim 17, wherein the nucleic acid sequence is associated with a polynucleotide coding for a protein or a polypeptide.

Please add the following new claims:

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

145859

- 6 -